Articles related to PROSTATE CANCER

“At 10 years, BCF was 38.0% for HDR compared with 10.4% for SBRT.” — Udovicich et al., JAMA Network Open, February 2026

“The WOLVERINE meta-analysis provides the strongest evidence to date that MDT improves progression-free survival, radiographic progression-free survival, and castration resistance-free survival.” — Tang et al., The Lancet Oncology

Despite the scale of prostate-specific antigen (PSA) testing for prostate cancer screening, prediction models do not predict time-to-event end points or adjust for patient life expectancy.

Although men in this cohort have a good prognosis, this finding is clinically relevant, as change in PSA is a factor in determining whether men opt to remain on [active surveillance].

The results of PROfound and PROpel underscore the importance of identifying the genomic characteristics of the patient and the cancer to guide the selection of the most appropriate treatment for a specific patient type.

The prevalence of HRR deficiencies has been found to be as high as 20% to 30% in patients with mCRPC, a significantly higher rate than that in patients with localized disease.